You are here

  • Home
  • Archive
  • Volume 10, Issue 3
  • IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer

 

Online download statistics by month:

Online download statistics by month: March 2022 to November 2024

AbstractFullPdf
Mar 2022381381105
Apr 2022404410100
May 202226326990
Jun 202212851308190
Jul 202238339071
Aug 202229329847
Sep 202223723736
Oct 202232933772
Nov 202224124154
Dec 202219919947
Jan 202314014129
Feb 202318318338
Mar 202319820175
Apr 202313413458
May 202310510523
Jun 202310911035
Jul 202313013137
Aug 202310810728
Sep 202310210520
Oct 202312612731
Nov 202310110233
Dec 202311311649
Jan 2024808030
Feb 2024898935
Mar 202412712781
Apr 2024898941
May 202411211339
Jun 2024969829
Jul 2024888841
Aug 2024828019
Sep 2024999938
Oct 2024787824
Nov 2024858627
Total658966591672